Aspirin use and potential mechanisms for colorectal cancer prevention

Journal of Clinical Investigation

Volumn 100, Issue 6, 1997, Pages 1325-1329

  Williams, Christopher S ^b,c   Smalley, Walter ^a,c   DuBois, Raymond N ^a,b,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CARCINOGEN; CYCLOHEXIMIDE; ENDOPEROXIDE; GLUCOCORTICOID; ICOSANOID; MESSENGER RNA; MITOGENIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; SULINDAC; THROMBOXANE;

ADENOMATOUS POLYP; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CEREBROVASCULAR ACCIDENT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLORECTAL CANCER; GASTROINTESTINAL HEMORRHAGE; GENE; HEART INFARCTION; HUMAN; MORTALITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PEPTIC ULCER; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SIGMOIDOSCOPY;

EID: 0030770386     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119651     Document Type: Review

References (47)

1. Smalley, W., and R.N. DuBois. 1997. Colorectal cancer and non steroidal anti-inflammatory drugs. Adv. Pharmacol. 39:1-20.
2. Peleg, I.I., M.F. Lubin, G.A. Cotsonis, W.S. Clark, and C.M. Wilcox. 1996. Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia. Dig. Dis. Sci. 41:1319-1326.
3. Giovannucci, E., K.M. Egan, D.J. Hunter, M.J. Stampfer, G.A. Colditz, W.C. Willett, and F.E. Speizer. 1995. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med. 333:609-614.
4. Giardiello, F.M., G.J.A. Offerhaus, and R.N. DuBois. 1995. The role of nonsteroidal antiinflammatory drugs in colorectal cancer prevention. Eur. J. Cancer. 31(A):1071-1076.
5. Gann, P.H., J.E. Manson, R.J. Glynn, J.E. Buring, and C.H. Hennekens. 1993. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J. Natl. Cancer Inst. 85:1220-1224.
6. Miyaki, M., M. Konishi, R. Kikuchi-Yanoshita, M. Enomoto, T. Igari, K. Tanaka, M. Muraoka, H. Takahashi, Y. Amada, M. Fukayama, et al. 1994. Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumors. Cancer Res. 54:3011-3020.
7. Powell, S.M., N. Zilz, Y. Beazer-Barclay, T.M. Bryan, S.R. Hamilton, S.N. Thibodeau, B. Vogelstein, and K.W. Kinzler. 1992. APC mutations occur early during colorectal tumorigenesis. Nature (Lond.). 359:235-237.
8. Waddell, W.R., and R.W. Loughry. 1983. Sulindac for polyposis of the colon. J. Surg. Oncol. 24:83-87.
9. Labayle, D., D. Fischer, P. Vielh, F. Drouhin, A. Pariente, C. Bories, O. Duhamel, M. Trousset, and P. Attali. 1991. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology. 101:635-639.
10. Giardiello, F.M., S.R. Hamilton, A.J. Krush, S. Piantadosi, L.M. Hylind, P. Celano, S.V. Booker, C.R. Robinson, and G.J. Offerhaus. 1993. Treatment of colonie and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 328:1313-1316.
11. 10a. Nugent, K.P., K.C. Farmer, A.D. Spigelman, C.B. Williams, and R.K. Phillips. 1993. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br. J. Surg. 80:1618-1619.
12. Miyamoto, T., N. Ogino, S. Yamamoto, and O. Hayaishi. 1976. Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J. Biol. Chem. 251:2629-2636.
13. Raz, A., A. Wyche, N. Siegel, and P. Needleman. 1988. Regulation of fibroblast cyclooxyaenase synthesis by interleukin-1. J. Biol. Chem. 263:3022-3028.
14. Simmons, D.L., D.B. Levy, Y. Yannoni, and R.L. Erikson. 1989. Identification of a phorbol ester-repressible v-src-inducible gene. Proc. Natl. Acad. Sci. USA. 86:1178-1182.
15. Kujubu, D.A., B.S. Fletcher, B.C. Varnum, R.W. Lim, and H.R. Herschman. 1991. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem. 266:12866-12872.
16. Williams, C.S., and R.N. DuBois. 1996. Prostaglandin endoperoxide synthase: why two isoforms? Am. J. Physiol. 270:G393-G400.
17. DuBois, R.N., M. Tsujii, P. Bishop, J.A. Awad, K. Makita, and A. Lanahan. 1994. Cloning and characterization of a growth factor-inducible cyclooxygenase gene from rat intestinal epithelial cells. Am. J. Physiol. 266:G822-G827.
18. DeWitt, D.L., and E.A. Meade. 1993. Serum and glucocorticoid regulation of gene transcription and expression of prostaglandin H synthase-1 and prostaglandin H synthase-2 isozymes. Arch. Biochem. Biophys. 306:94-102.
19. DuBois, R.N., J. Awad, J. Morrow, L.J. Roberts, and P.R. Bishop. 1994. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-α and phorbol ester. J. Clin. Invest. 93:493-498.
20. Eberhart, C.E., R.J. Coffey, A. Radhika, F.M. Giardiello, S. Ferrenbach, and R.N. DuBois. 1994. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 107:1183-1188.
21. Sano, H., Y. Kawahito, R.L. Wilder, A. Hashiramoto, S. Mukai, K. Asai, S. Kimura, H. Kato, M. Kondo, and T. Hla. 1995. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 55:3785-3789.
22. Kargman, S., G. O'Neill, P. Vickers, J. Evans, J. Mancini, and S. Jothy. 1995. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res. 55:2556-2559.
23. DuBois, R.N., A. Radhika, B.S. Reddy, and A.J. Entingh. 1996. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonie tumors. Gastroenterology. 110:1259-1262.
24. Williams, C.S., C. Luongo, A. Radhika, T. Zhang, L.W. Lamps, L.B. Nanney, R.D. Beauchamp, and R.N. DuBois. 1996. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology. 111:1134-1140.
25. Tsujii, M., and R.N. DuBois. 1995. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell. 83:493-501.
26. Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res. 56:710-714.
27. Boolbol, S.K., A.J. Dannenberg, A. Chadburn, C. Martucci, X.J. Guo, J.T. Ramonetti, M. Abreu-Goris, H.L. Newmark, M.L. Lipkin, J.J. DeCosse, and M.M. Bertagnolli. 1996. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 56:2556-2560.
28. Reddy, B.S. 1996. Chemoprevention of colon cancer by minor dietary constituents and their synthetic analogues. Prev. Med. 25:48-50.
29. Δ716 knockout mice by inhibition of prostaglandin endoperoxide synthase-2 (COX-2). Cell. 87:803-809.
30. Masferrer, J.L., B.S. Zweifel, P.T. Manning, S.D. Hauser, K.M. Leahy, W.G. Smith, P.C. Isakson, and K. Seibert. 1994. Selective inhibition of inducible cyclooxygenase-2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. USA. 91:3228-3232.
31. O'Neill, G.P., J.A. Mancini, S. Kargman, J. Yergey, M.Y. Kwan, J.P. Falgueyret, M. Abramovitz, B.P. Kennedy, M. Ouellet, W. Cromlish, et al. 1994. Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid. Mol. Pharmacol. 45:245-254.
32. Sheng, H., J. Shao, S.C. Kirkland, P. Isakson, R. Coffey, J. Morrow, R.D. Beauchamp, and R.N. DuBois. 1997. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J. Clin. Invest. 99:2254-2259.
33. Hanif, R., A. Pittas, Y. Feng, M.I. Koutsos, L. Qiao, L. Staiano-Coico, S.I. Shiff, and B. Rigas. 1996. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem. Pharmacol. 52:237-245.
34. Shiff, S.J., M.I. Koutsos, L. Qiao, and B. Rigas. 1996. Nonsteroidal anti-inflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp. Cell Res. 222:179-188.
35. Piazza, G.A., A.L. Rahm, M. Krutzsch, G. Sperl, N.S. Paranka, P.M. Gross, K. Brendel, R.W. Burt, D.S. Alberts, R. Pamukcu, and D.J. Ahnen. 1995. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res. 55:3110-3116.
36. Eberhart, C.E., and R.N. DuBois. 1995. Eicosanoids and the gastrointestinal tract. Gastroenterology. 109:285-301.
37. Scheiman, J.M. 1996. NSAIDs, gastrointestinal injury and cytoprotection. Gastroenterol. Clin. North Am. 25:279-298.
38. Thompson, H.J., C. Jiang, J.X. Lu, R.G. Mehta, G.A. Piazza, N.S. Paranka, R. Pamukcu, and D.J. Ahnen. 1997. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res. 57:267-271.
39. Egan, K.M., M.J. Stampfer, E. Giovannucci, B.A. Rosner, and G.A. Colditz. 1996. Prospective study of regular aspirin use and the risk of breast cancer. J. Natl. Cancer Inst. 88:988-993.
40. DuBois, R.N., and W.E. Smalley. 1996. Cyclooxygenase, NSAIDs and colorectal cancer. J. Gastroenterol. 31:898-906.
41. Anti-Platelet Trialists' Collaboration. 1988. Secondary prevention of vascular disease by prolonged anti platelet treatment. Br. Med. J. 296:320-321.
42. U.S. Preventive Services Task Force. 1996. In Guide to Clinical Preventive Services. International Medical Publishing, Alexandria, Virginia. 845-851.
43. Physicians' Health Study Group. 1989. Final report on the aspirin component of the ongoing Physicians' Health Study. N. Engl. J. Med. 321:129-135.
44. Peto, R., R. Gray, R. Collins, K. Wheatley, C. Hennekens, K. Jamrozik, C. Warlow, B. Hafner, E. Thompson, S. Norton, et al. 1988. Randomised trial of prophylactic daily aspirin in British male doctors. B.M.J. (Clin. Res. Ed.). 296: 313-316.
45. Manson, J.E., M.J. Stampfer, G.A. Colditz, W.C. Willett, B. Rosner, F.E. Speizer, and C.H. Hennekens. 1991. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA (J. Am. Med. Assoc.). 266:521-527.
46. Smalley, W.E., and M.R. Griffin. 1996. The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Gastroenterol. Clin. North Am. 25:373-396.
47. Willett, L.R., J.L. Carson, and B.L. Strom. 1994. Epidemiology of gastrointestinal damage associated with nonsteroidal anti-inflammatory drugs. Drug Saf. 10:170-181.